Drug-induced psychosis after long-term treatment with levetiracetam [9]

Canadian Journal of Psychiatry

Volumn 49, Issue 12, 2004, Pages 868-

  Bayerlein, Kristina ^a   Frieling, Helge ^a   Beyer, Barabara ^a   Kornhuber, Johannes ^a   Bleich, Stefan ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

DIAZEPAM; ETIRACETAM; LAMOTRIGINE; LORAZEPAM; OLANZAPINE; PRIMIDONE; ZUCLOPENTHIXOL;

ADULT; AGGRESSION; AGITATION; AUDITORY HALLUCINATION; CASE REPORT; DOSE RESPONSE; DRUG DOSE REDUCTION; FEMALE; HUMAN; LETTER; LONG TERM CARE; MYOCLONUS EPILEPSY; NERVOUSNESS; PATIENT MONITORING; PSYCHOSIS; RISK FACTOR;

ADULT; FEMALE; HUMANS; NOOTROPIC AGENTS; PIRACETAM; PSYCHOSES, SUBSTANCE-INDUCED; TIME;

EID: 12744253715     PISSN: 07067437     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (5)

1. Kossoff EH, Bergey GK, Freeman JM, Vining EP. Levetiracetam psychosis in children with epilepsy. Epilepsia 2001;12:1611-3.
2. Youroukos S, Lazopoulou D, Michelakou D, Karagianni J. Acute psychosis associated with levetiracetam. Epileptic Disord 2003;2:117-9.
3. Ben Menachem E and Gilland E. Efficacy and tolerability of levetiracetam during 1-year follow-up in patients with refractory epilepsy. Seizure 2003;3:131-5.
4. Cramer JA, De Rue K, Devinsky O, Edrich P, Trimble MR. A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials. Epilepsy Behav 2003;2:124-32.
5. Mula M, Trimble MR, Yuen A, Liu RS, Sander JW. Psychiatric adverse events during levetiracetam therapy. Neurology 2003;5:704-6.